Insmed, Inc. $INSM Shares Sold by Groupama Asset Managment

Groupama Asset Managment lessened its holdings in Insmed, Inc. (NASDAQ:INSM) by 57.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,590 shares of the biopharmaceutical company’s stock after selling 7,585 shares during the period. Groupama Asset Managment’s holdings in Insmed were worth $973,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock valued at $3,668,127,000 after purchasing an additional 1,140,524 shares in the last quarter. Darwin Global Management Ltd. lifted its stake in shares of Insmed by 2.3% during the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock worth $3,644,274,000 after purchasing an additional 475,832 shares in the last quarter. Capital International Investors boosted its position in shares of Insmed by 1.0% in the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after buying an additional 74,994 shares during the period. State Street Corp boosted its position in shares of Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after buying an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership grew its stake in shares of Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares in the last quarter.

Analysts Set New Price Targets

INSM has been the topic of several recent research reports. Barclays boosted their price target on Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Mizuho set a $192.00 target price on shares of Insmed in a research report on Tuesday. Royal Bank Of Canada decreased their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Finally, Raymond James Financial began coverage on shares of Insmed in a report on Friday, April 10th. They set an “outperform” rating and a $200.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $211.86.

Insider Activity at Insmed

In related news, insider Michael Alexander Smith sold 2,159 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $220,800.93. Following the sale, the insider directly owned 39,454 shares of the company’s stock, valued at $4,034,960.58. This represents a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Sara Bonstein sold 2,404 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the transaction, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. This trade represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 149,783 shares of company stock worth $22,902,672 in the last ninety days. 2.10% of the stock is currently owned by corporate insiders.

Insmed Price Performance

Shares of NASDAQ INSM opened at $95.70 on Friday. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The business has a 50 day moving average price of $117.97 and a two-hundred day moving average price of $147.47. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The firm has a market cap of $20.74 billion, a PE ratio of -16.64 and a beta of 0.79.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.Insmed’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period in the prior year, the company posted ($1.42) EPS. Sell-side analysts expect that Insmed, Inc. will post -2.54 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.